Associated Papers
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway.
Liu N et al.
International Journal of Biological Sciences, 2022
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
Bhatia A et al.
Neuro-oncology, 2020
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH et al.
Nature Medicine, 2019
31768065 (PubMed )
Supplement: NIHMS1541330-supplement-1.pdf
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y et al.
Journal for Immunotherapy of Cancer, 2019
30944026 (PubMed )
Supplement: 40425_2019_581_MOESM3_ESM.pdf
Efficacy of MEK inhibition in patients with histiocytic neoplasms.
Diamond EL et al.
Nature, 2019
Novel KRAS gene mutations in sporadic colorectal cancer.
Naser WM et al.
Plos One, 2014
Select a paper to view details